1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
January 2022 in “eJournal Kedokteran Indonesia” Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.
March 2009 in “Dermatology Online Journal” Manipulating EGFR signaling may help treat hair loss and promote hair growth.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
April 2025 in “JAAD Case Reports” Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
21 citations
,
March 2022 in “Pharmaceuticals” The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.
1 citations
,
September 2025 in “The Oncologist” Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
April 2024 in “Canadian Journal of Ophthalmology” A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.
1 citations
,
May 2017 in “Journal of cosmetic and laser therapy” Lasers can help reduce skin side effects from cancer treatment.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
February 2023 in “Pharmaceutics”
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
June 2025 in “Acta Dermato Venereologica” Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
Suppressing ODC activity reduces tumor growth in hair follicles.
36 citations
,
January 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The document concludes that understanding genetic mutations in the PI3K-AKT-mTOR pathway can lead to better diagnosis and treatment for certain genetic skin disorders.
3 citations
,
October 2018 in “Journal of Mind and Medical Sciences” Biological therapy boosts the immune system to effectively fight melanoma.
4 citations
,
September 2010 in “Medical Hypotheses” Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
3 citations
,
September 2021 in “Journal of Investigative Dermatology” Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
September 2023 in “Journal of the American Academy of Dermatology”